Nov 01, 2023 / NTS GMT
Presentation
Nov 01, 2023 / NTS GMT
=====================
Corporate Participants
=====================
* Atsushi Kitamura
Astellas Pharma Inc. - CFO
* Claus Zieler
Astellas Pharma Inc. - Chief Commercial Officer
* Hiromitsu Ikeda
Astellas Pharma Inc. - Corporate Head of Advocacy & Relations
* Naoki Okamura
Astellas Pharma Inc. - President, CEO & Director
* Tadaaki Taniguchi
Astellas Pharma Inc. - Chief Medical Officer
=====================
Conference Call Participants
=====================
* Akinori Ueda
Goldman Sachs Group, Inc., Research Division - Equity Analyst
* Fumiyoshi Sakai
UBS Investment Bank, Research Division - Research Analyst
* Hidemaru Yamaguchi
Citigroup Inc., Research Division - Research Analyst
* Kazuaki Hashiguchi
Daiwa Securities Co. Ltd., Research Division - Research Analyst
* Miki Sogi
Sanford C. Bernstein & Co., LLC., Research Division - Research Analyst
* Seiji Wakao
JPMorgan
Astellas Pharma Inc
(OTCPK:ALPMY)
$
13.73
-0.69 (-4.79%)
Market Cap: 24.60 Bil
Enterprise Value: 26.29 Bil
PE Ratio: 12.80
PB Ratio: 2.21
GF Score: 81/100 Q2 2024 Astellas Pharma Inc Earnings Presentation Transcript
Nov 01, 2023 / NTS GMT
Release Date Price:
$12.16
(-4.19%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot